Identifying subsets of patients who will respond to subsequent lines of chemotherapy
In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy. Dr Bernardo's group analysed data from 980 women treated with chemotherapy for metastatic breast cancer in their centre between 1992 and 2006.
They found that the median overall survival grew progressively smaller for each successive chemotherapy regimen the patients were given. The time to treatment failure also shortened as each new regimen was tried, from a median of 9.2 months for first-line therapy, to 7.8 and 6.4 months for the second and third-line drugs. Beyond the third line, there was no significant decrease in the medial time to treatment failure for each successive therapy.
The researchers found that only one factor they analysed affected a patient's overall survival time. That factor was the time to treatment failure for each line of chemotherapy. In other words, the more benefit one type of therapy offered, the more benefit the subsequent therapy was likely to offer.
"The implications of our analysis for clinical practice concern the possibility of deciding which patients should be offered a third- or successive chemotherapy line, considering that there are multiple treatment options available today for metastatic disease, and increasing numbers of patients ask for more options when a particular treatment fails," said Dr Bernardo.
Source: European Society for Medical Oncology
Articles on the same topic
- New Phase II study shows first-line promise of lung cancer drug PF-299Tue, 12 Oct 2010, 15:35:26 UTC
- Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancerTue, 12 Oct 2010, 15:35:24 UTC
- High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myelomaTue, 12 Oct 2010, 14:36:15 UTC
- Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRCTue, 12 Oct 2010, 14:36:14 UTC
- Study finds breast-feeding safe for women after breast cancer treatmentTue, 12 Oct 2010, 14:06:33 UTC
- Surgical technique relieves painful spine fractures in patients with metastatic cancerSat, 9 Oct 2010, 7:32:39 UTC
- Targeted therapy promising for HER2-positive metastatic breast cancerFri, 8 Oct 2010, 16:06:07 UTC
Other sources
- Breast-feeding safe for women after breast cancer treatment, study findsfrom Science DailyThu, 14 Oct 2010, 3:30:41 UTC
- Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancerfrom PhysorgTue, 12 Oct 2010, 23:01:17 UTC
- Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRCfrom PhysorgTue, 12 Oct 2010, 16:04:04 UTC
- Study finds breast-feeding safe for women after breast cancer treatmentfrom PhysorgTue, 12 Oct 2010, 16:04:02 UTC
- High response rates seen in phase-III trial of chemotherapy, new drug and stem cells in myelomafrom PhysorgTue, 12 Oct 2010, 14:31:27 UTC
- Surgical technique relieves painful spine fractures in patients with metastatic cancerfrom Science BlogSun, 10 Oct 2010, 14:20:26 UTC
- Surgical technique relieves painful spine fractures in patients with metastatic cancerfrom PhysorgSat, 9 Oct 2010, 10:01:37 UTC
- Targeted therapy promising for HER2-positive metastatic breast cancerfrom Science DailyFri, 8 Oct 2010, 18:10:55 UTC
- Targeted therapy promising for HER2-positive metastatic breast cancerfrom Science BlogFri, 8 Oct 2010, 18:00:39 UTC
- Targeted therapy promising for HER2-positive metastatic breast cancerfrom PhysorgFri, 8 Oct 2010, 18:00:18 UTC
- New cancer therapy appears promising in pre-clinical trailsfrom PhysorgWed, 6 Oct 2010, 14:20:46 UTC
- First stem cell clinical trial describedfrom UPIMon, 4 Oct 2010, 18:32:11 UTC